Acadia Pharmaceuticals.
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.
- Reports this week
- 2
- Active events
- 2
- Connections
- 53
What's happening
Active this week
One to three months ago
-
Financial institutions (Morgan Stanley, BofA, Norges Bank, Millennium Management) made various market moves and issued research notes regarding Acadia Pharmaceuticals.Some support1 report
-
Acadia Pharmaceuticals reported revenue growth driven by product launches and market penetration.Some support1 report
-
Immunic, Inc. appointed Elena Ridloff to its board, who previously held the CFO role at Acadia Pharmaceuticals.Some support1 report
-
Rating changes were reported for several companies on August 8, 2026, including upgrades from hold to buy and sell to hold.Some support1 report
-
Acadia Pharmaceuticals is seeking European market access for product launches, with a specific launch planned for Germany in early Q4.Some support1 report
Gone quiet
No new reports in 90+ days-
Acadia Pharmaceuticals received final market authorization in the EU for its drug DAYBU after receiving a positive opinion from the European Medicines Agency.Some support3 reports
-
Acadia Pharmaceuticals and Amarin are competing in the biopharmaceutical market.Some support2 reports
-
Tina Katcheves gained professional experience from both Teva Pharmaceuticals and Bristol Myers Squibb on August 27, 2025, involving Acadia Pharmaceuticals.Some support2 reports
-
Trump-era tariffs are noted to offer potential upside, impacting AI stocks and international expansion involving Acadia Pharmaceuticals and Europe.Some support2 reports
-
RBC raised price target on Alnylam Pharmaceuticals on July 7, 2025.Speculative2 reports
-
Acadia Pharmaceuticals is initiating a Phase 3 study for its drug trofinetide in Japan.Speculative1 report
-
Leerink Partners assessed forecasts and Mizuho Securities analysts provided sales estimates for Acadia Pharmaceuticals on June 26, 2025.Speculative1 report
-
Acadia Pharmaceuticals, based in San Diego, was the subject of a Zacks analyst survey regarding earnings on August 7, 2025.Some support4 reports1 development inside
-
Acadia Pharmaceuticals and Genmab A/S Sponsored ADR were analyzed for value investment potential on August 1, 2025.Some support1 report
-
Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.Some support1 report
-
Acadia Pharmaceuticals developed and commercialized medicines in the United States on August 15, 2025.Some support3 reports
-
A career profile of James M. Daly detailing his appointments at Cytokinetics, Amgen, and GlaxoSmithKline.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Acadia Pharmaceuticals this week
News at the entities that move Acadia Pharmaceuticals most-
Securities and Exchange Commission StructuralNYSE and Nasdaq plan to expand trading hours and file updated rules with the SEC.Moves Acadia Pharmaceuticals
-
European Medicines Agency StructuralGlenn attended a congress in Amsterdam and participated in a panel with an official from the European Medicines Agency.Moves Acadia Pharmaceuticals
-
Norges Bank TransactionalAmundi and Norges Bank increased their stakes in GE Aerospace, while Mohamed Ali sold shares, leading to SEC filings.Moves Acadia Pharmaceuticals
-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Acadia Pharmaceuticals
-
Morgan Stanley Mentioned togetherCitigroup upgraded Next plc to a buy rating, while Santander and Morgan Stanley also issued rating updates on the company.Moves Acadia Pharmaceuticals
-
Nasdaq StructuralA Vertex employee won an Info-Tech award, the company is listed on Nasdaq, and Sarah Vlasic leads Leadership Circles at the University of Colorado Boulder.Moves Acadia Pharmaceuticals
Connections
The 17 strongest of 53, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Securities and Exchange Commission Structural
Acadia Pharmaceuticals is formally required to file with the SEC regarding institutional investment transparency.
-
Bank of America Mentioned together
Bank of America provides financial ratings and price targets for Acadia Pharmaceuticals stock.
-
European Medicines Agency Structural
The EMA formally reviews Acadia's drug applications for European market access and approval.
-
Norges Bank Transactional
Norges Bank is currently acquiring shares in Acadia Pharmaceuticals.
-
FDA Structural
Acadia Pharmaceuticals relies on the FDA for the approval of its pharmaceutical products.
-
Geode Capital Management Transactional
Geode Capital Management increased its investment holdings in Acadia Pharmaceuticals.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial research and coverage on Acadia Pharmaceuticals.
-
Millennium Management Transactional
Millennium Management increased its stake in Acadia Pharmaceuticals as part of a specific investment action.
Show all 17 connections
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial analysis and updates stock price targets for Acadia Pharmaceuticals.
-
Citigroup Mentioned together
Citigroup provides positive investment ratings and target price boosts for Acadia Pharmaceuticals' shares.
-
Nasdaq Structural
Acadia Pharmaceuticals maintains a structural relationship with Nasdaq by listing its stock on the exchange.
-
MarketBeat Mentioned together
MarketBeat reports consensus ratings and target prices for Acadia Pharmaceuticals.
-
Europe Shared context
Acadia Pharmaceuticals operates within the regulatory and market context of Europe, as evidenced by EU approval recommendations.
-
Aurobindo Pharma Operational
Acadia Pharmaceuticals and Aurobindo Pharma are engaged in legal competition regarding intellectual property rights.
-
James Kihara Mentioned together
A is linked to B through the context of insider news mentioning B.
-
Sydney Shared context
Sydney serves as the geographical and market context for Acadia Pharmaceuticals' operations, which were recently impacted by a positive regulatory recommendation.
-
San Diego Shared context
Acadia Pharmaceuticals is located in San Diego.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
1 eventAugust 2026
4 events- Acadia Pharmaceuticals reported revenue growth driven by product launches and market penetration.
- Immunic, Inc. appointed Elena Ridloff to its board, who previously held the CFO role at Acadia Pharmaceuticals.
- Rating changes were reported for several companies on August 8, 2026, including upgrades from hold to buy and sell to hold.
- Acadia Pharmaceuticals is seeking European market access for product launches, with a specific launch planned for Germany in early Q4.
Show 1 earlier month
June 2026
13 events- Citigroup and Bank of America issued rating updates for Acadia Pharmaceuticals, alongside insider news regarding James Kihara.
- Acadia Pharmaceuticals received final market authorization in the EU for its drug DAYBU after receiving a positive opinion from the European Medicines Agency.
- Acadia Pharmaceuticals and Amarin are competing in the biopharmaceutical market.
- Tina Katcheves gained professional experience from both Teva Pharmaceuticals and Bristol Myers Squibb on August 27, 2025, involving Acadia Pharmaceuticals.
- Trump-era tariffs are noted to offer potential upside, impacting AI stocks and international expansion involving Acadia Pharmaceuticals and Europe.
- RBC raised price target on Alnylam Pharmaceuticals on July 7, 2025.
- Acadia Pharmaceuticals is initiating a Phase 3 study for its drug trofinetide in Japan.
- Leerink Partners assessed forecasts and Mizuho Securities analysts provided sales estimates for Acadia Pharmaceuticals on June 26, 2025.
- Acadia Pharmaceuticals, based in San Diego, was the subject of a Zacks analyst survey regarding earnings on August 7, 2025.
- Acadia Pharmaceuticals and Genmab A/S Sponsored ADR were analyzed for value investment potential on August 1, 2025.
- Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.
- Acadia Pharmaceuticals developed and commercialized medicines in the United States on August 15, 2025.
- A career profile of James M. Daly detailing his appointments at Cytokinetics, Amgen, and GlaxoSmithKline.